156 related articles for article (PubMed ID: 7693904)
1. Treatment with lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) and orthotopic liver transplantation for glycogen storage disease type Ib.
Lachaux A; Boillot O; Stamm D; Canterino I; Dumontet C; Regnier F; Floret D; Hermier M
J Pediatr; 1993 Dec; 123(6):1005-8. PubMed ID: 7693904
[TBL] [Abstract][Full Text] [Related]
2. Orthotopic liver transplantation for glycogen storage disease type Ib--treatment with recombinant human granulocyte colony-stimulating factor.
Lachaux A; Boillot O; Stamm D; Canterino I; Regnier F; Regragui K; Floret D; Hermier M
Transplant Proc; 1994 Feb; 26(1):265. PubMed ID: 7509094
[No Abstract] [Full Text] [Related]
3. Recombinant human G-CSF (Lenograstim) for infectious complications in glycogen storage disease type Ib. Report of 7 cases.
Donadieu J; Bader-Meunier B; Bertrand Y; Lachaux A; Labrune P; Gougerot-Pocidalo MA; Odièvre M; Gibeaud P; Yver A; Tchernia G
Nouv Rev Fr Hematol (1978); 1994; 35(6):529-34. PubMed ID: 7512258
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim).
Ono M
Eur J Cancer; 1994; 30A Suppl 3():S7-11. PubMed ID: 7535073
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte and granulocyte-macrophage colony-stimulating factors for treatment of neutropenia in glycogen storage disease type Ib.
Schroten H; Roesler J; Breidenbach T; Wendel U; Elsner J; Schweitzer S; Zeidler C; Burdach S; Lohmann-Matthes ML; Wahn V
J Pediatr; 1991 Nov; 119(5):748-54. PubMed ID: 1719175
[TBL] [Abstract][Full Text] [Related]
6. Effects of molgramostim, filgrastim and lenograstim in the treatment of myelokathexis.
Cernelc P; Andoljsek D; Mlakar U; Pretnar J; Modic M; Zupan IP; Zver S
Pflugers Arch; 2000; 440(5 Suppl):R81-2. PubMed ID: 11005621
[TBL] [Abstract][Full Text] [Related]
7. A European phase II study of recombinant human granulocyte colony-stimulating factor (lenograstim) in the treatment of severe chronic neutropenia in children. Lenograstim Study Group.
Donadieu J; Boutard P; Bernatowska E; Tchernia G; Couillaud G; Philippe N; Le Gall E
Eur J Pediatr; 1997 Sep; 156(9):693-700. PubMed ID: 9296532
[TBL] [Abstract][Full Text] [Related]
8. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group.
Dombret H; Chastang C; Fenaux P; Reiffers J; Bordessoule D; Bouabdallah R; Mandelli F; Ferrant A; Auzanneau G; Tilly H
N Engl J Med; 1995 Jun; 332(25):1678-83. PubMed ID: 7539109
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte colony-stimulating factor corrects the neutropenia associated with glycogen storage disease type Ib.
Wang WC; Crist WM; Ihle JN; Arnold BA; Keating JP
Leukemia; 1991 Apr; 5(4):347-9. PubMed ID: 1709246
[TBL] [Abstract][Full Text] [Related]
10. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.
Dunn CJ; Goa KL
Drugs; 2000 Mar; 59(3):681-717. PubMed ID: 10776839
[TBL] [Abstract][Full Text] [Related]
11. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation.
Gisselbrecht C; Prentice HG; Bacigalupo A; Biron P; Milpied N; Rubie H; Cunningham D; Legros M; Pico JL; Linch DC
Lancet; 1994 Mar; 343(8899):696-700. PubMed ID: 7510813
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemia.
Takeshita A; Saito H; Toyama K; Horiuchi A; Kuriya S; Furusawa S; Tsuruoka N; Takiguchi T; Matsuda T; Utsumi M; Shiku H; Matsui T; Egami K; Tamura K; Ohno R
Int J Hematol; 2000 Feb; 71(2):136-43. PubMed ID: 10745623
[TBL] [Abstract][Full Text] [Related]
13. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.
Gisselbrecht C; Haioun C; Lepage E; Bastion Y; Tilly H; Bosly A; Dupriez B; Marit G; Herbrecht R; Deconinck E; Marolleau JP; Yver A; Dabouz-Harrouche F; Coiffier B; Reyes F
Leuk Lymphoma; 1997 Apr; 25(3-4):289-300. PubMed ID: 9168439
[TBL] [Abstract][Full Text] [Related]
14. Effect of lenograstim on the cost of autologous bone marrow transplantation. A preliminary communication.
Brice P; Godin S; Libert O; Marolleau JP; Makki J; Extra JM; Faure P; Gisselbrecht C
Pharmacoeconomics; 1995 Mar; 7(3):238-41. PubMed ID: 10155313
[TBL] [Abstract][Full Text] [Related]
15. Glycogen storage disease type Ib: infectious complications and measures for prevention.
Wendel U; Schroten H; Burdach S; Wahn V
Eur J Pediatr; 1993; 152 Suppl 1():S49-51. PubMed ID: 7686491
[TBL] [Abstract][Full Text] [Related]
16. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.
Frampton JE; Yarker YE; Goa KL
Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335
[TBL] [Abstract][Full Text] [Related]
17. Liver transplantation for type Ib glycogenosis with reversal of cyclic neutropenia.
Martinez-Olmos MA ; López-Sanromán A; Martín-Vaquero P; Molina-Pérez E; Bárcena R; Vicente E; Candela A ; Pallardo-Sánchez LF
Clin Nutr; 2001 Aug; 20(4):375-7. PubMed ID: 11478837
[TBL] [Abstract][Full Text] [Related]
18. Improvement of neutropenia and neutrophil dysfunction by granulocyte colony-stimulating factor in a patient with glycogen storage disease type Ib.
Ishiguro A; Nakahata T; Shimbo T; Amano Y; Yasui K; Koike K; Komiyama A
Eur J Pediatr; 1993 Jan; 152(1):18-20. PubMed ID: 7680314
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo effects of granulocyte colony-stimulating factor on neutrophils in glycogen storage disease type 1B: granulocyte colony-stimulating factor therapy corrects the neutropenia and the defects in respiratory burst activity and Ca2+ mobilization.
McCawley LJ; Korchak HM; Douglas SD; Campbell DE; Thornton PS; Stanley CA; Baker L; Kilpatrick L
Pediatr Res; 1994 Jan; 35(1):84-90. PubMed ID: 7510873
[TBL] [Abstract][Full Text] [Related]
20. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia.
Gluckman E; Rokicka-Milewska R; Hann I; Nikiforakis E; Tavakoli F; Cohen-Scali S; Bacigalupo A;
Br J Haematol; 2002 Dec; 119(4):1075-82. PubMed ID: 12472591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
